Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma
April 27, 2020 06:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Appoints Two New Members to Its Board of Directors
April 01, 2020 07:30 ET
|
Harpoon Therapeutics
Andrew R. Robbins, former Chief Operating Officer, Array BiopharmaDr. Joseph S. Bailes, former President of American Society of Clinical Oncology (ASCO) SOUTH SAN FRANCISCO, Calif., April 01, 2020 ...
Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update
March 12, 2020 16:05 ET
|
Harpoon Therapeutics
Exclusive worldwide option and license transaction for HPN217 with AbbVie and expansion of existing discovery collaboration in November 2019 could provide up to $100 million in upfront/near-term...
Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update
March 05, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
February 20, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference
November 26, 2019 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
November 21, 2019 04:00 ET
|
Harpoon Therapeutics; AbbVie Inc.
Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration...